Robert F. Degenring - Concepedia

Author

Robert F. Degenring

Also Known As

R Degenring, R F Degenring, R. Degenring, R. F. Degenring, R.F. Degenring, Robert Degenring, Robert F Degenring, Robert F. Degenring, Robert F. Degenring

Publications

2.1K

Citations

H-Index

Concepts

All Affiliations

Heidelberg University Augenklinik Heidelberg University Hospital Heidelberg University of Mannheim University Hospital Cologne

About

Robert F. Degenring is an author at Heidelberg University specializing in medicine, ophthalmology, and surgery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	14	14	1.2K
2	Diabetes	2	2	202
3	Vascular Surgery	2	2	237
4	Health Sciences	1	1	26
5	Anesthesia	1	1	72

Robert F. Degenring

Publications

1.5K

Citations

H-Index

Page 1

	Year	Citations
Intravitreal triamcinolone acetonide as treatment of macular edema in central retinal vein occlusion Jost B. Jonas, Ingrid Kreissig, Robert F. Degenring Graefe s Archive for Clinical and Experimental Ophthalmology Macular EdemaOcular DiseaseVitreous BodyOphthalmologyIntravitreal Triamcinolone	2002	207
Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema Jost B. Jonas, Ingrid Kreissig, Robert F. Degenring American Journal of Ophthalmology Ocular DiseaseVitreous BodyIntravitreal Triamcinolone AcetonideOphthalmologySurgery	2003	160
Branch retinal vein occlusion treated by intravitreal triamcinolone acetonide Jost B. Jonas, İmren Akkoyun, Bernd A. Kamppeter, Eye Ocular DiseaseVitreous BodyIntravitreal Triamcinolone AcetonideOphthalmologyVascular Surgery	2004	156
Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema Jost B. Jonas, Robert F. Degenring, Bernd A. Kamppeter, American Journal of Ophthalmology Diabetic RetinopathyOcular DiseaseVitreous BodyOphthalmologyIntravitreal Triamcinolone	2004	132
Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study Jost B. Jonas, Robert F. Degenring, Ingrid Kreissig, Eye Ocular DiseaseOphthalmologyIntravitreal Triamcinolone AcetonideExperimental OphthalmologyAge-related Diseases	2004	100
Choroidal neovascularisation secondary to Best’s disease in a 13-year-old boy treated by intravitreal bevacizumab Jörg Leu, Norbert Schrage, Robert F. Degenring Graefe s Archive for Clinical and Experimental Ophthalmology Ocular DiseaseVasculitisOphthalmologyVascular SurgeryChoroidal Neovascularisation	2007	81
Safety of intravitreal high-dose reinjections of triamcinolone acetonide Jost B. Jonas, Robert F. Degenring, Ingrid Kreissig, American Journal of Ophthalmology Minimally Invasive ProcedureThoracic SurgeryPostoperative TreatmentPharmacotherapySurgery	2004	72
Effect of uncomplicated phacoemulsification on the central retina in diabetic and non-diabetic subjects Robert F. Degenring, Sonja Vey, Bernd A. Kamppeter, Graefe s Archive for Clinical and Experimental Ophthalmology Diabetic RetinopathyUncomplicated PhacoemulsificationRetinaOphthalmologyExperimental Ophthalmology	2006	70
Morphological and functional changes after intravitreal triamcinolone acetonide for retinal vein occlusion Robert F. Degenring, Bernd A. Kamppeter, Ingrid Kreissig, Acta Ophthalmologica Scandinavica Ocular DiseaseVitreous BodyOphthalmologyIntravitreal Triamcinolone AcetonideMedicine	2003	60
Serum levels of triamcinolone acetonide after intravitreal injection Robert F. Degenring, Jost B. Jonas American Journal of Ophthalmology Therapeutic Drug MonitoringPharmacotherapyClinical ChemistryMedicinePharmacokinetics	2004	56

Page 1